Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 3 trial (SLE-BRAVE-II)

Targeted Small Molecules for Systemic Lupus Erythematosus: Drugs in the Pipeline

“…Serious AEs were numerically more common in the baricitinib than PBO groups. The rate of serious infection was higher in the [68,69] (Table 2). Participants were patients with autoantibody-positive SLE with ≥ 1 BILAG A or ≥ 2 BILAG B scores, total SLEDAI ≥ 6, and clinical SLEDAI ≥ 4 and were receiving background therapy with stable doses of GCs, a single antimalarial, or other immunosuppressive drug.…”

“…The favorable result of this phase II RCT led to two subsequent phase III RCTs of baricitinib in non-renal SLE (SLE-BRAVE I; NCT03616912 and SLE-BRAVE II; NCT03616964) [ 68 , 69 ] (Table 2 ). Participants were patients with autoantibody-positive SLE with ≥ 1 BILAG A or ≥ 2 BILAG B scores, total SLEDAI ≥ 6, and clinical SLEDAI ≥ 4 and were receiving background therapy with stable doses of GCs, a single antimalarial, or other immunosuppressive drug.…”

From concept to reality: CAR‐T therapy as a glimmer of hope for systemic lupus erythematosus patients

“…Inbaricitinib'sphaseIIItrialsforSLE,inconsistentresultswereob-servedintheSLEBRAVE-IandSLEBRAVE-IItrials. [14][15][16] Weshould expectmorechoicesformitigatingSLEactivity,whichwillfacilitate rapiddrugdevelopment.…”

Systemic lupus erythematosus complicated with cardiovascular disease

“…A recently completed large‐scale study of pioglitazone in the treatment of SLE, evaluating cardiovascular risk markers, found a positive effect of pioglitazone on cardiometabolic parameters, 16 and a therapeutic effect of pioglitazone by reducing CD4 + T‐cell activation and proliferation, enhancing Treg cell function and proliferation, and decreasing interferon‐γ (IFN‐γ) synthesis 17 . The IFN‐γ receptor‐targeting drug anifrolumab and the Janus kinase inhibitor tofacitinib reduced cardiovascular risk in SLE patients by inhibiting the IFN‐γ pathway and improving the severity of the disease and its associated vascular damage 18–20 …”

“…17 The IFNγ receptortargeting drug anifrolumab and the Janus kinase inhibitor tofacitinib reduced cardiovascular risk in SLE patients by inhibiting the IFNγ pathway and improving the severity of the disease and its associated vascular damage. [18][19][20] The immune and inflammatory features of SLE drive the development of CVD, and we need to explore the pathogenesis of SLE in more detail, mitigate the damage to the organs and systems of the body from its pathology, and continuously improve cardiovascular risk screening and monitoring capabilities to prevent the development of CVD in SLE patients.…”